-+ 0.00%
-+ 0.00%
-+ 0.00%
Eli Lilly Partners with Stipple Bio on Oncology Research
Share
Listen to the news
12:21 AM EST, 11/17/2026 (MT Newswires) -- Eli Lilly (LLY.F, LLY.SW) entered into a multi-target research collaboration and license agreement with Stipple Bio to develop targeted cancer therapies. Under the agreement, the biotechnology company is eligible for potential milestone payments of up to $5.9 billion, according to a Monday release. Stipple Bio will receive an upfront payment and an equity investment, and is eligible for tiered royalties on product sales. Eli Lilly will receive exclusive development and commercialization rights to products from the collaboration. As part of the contract, Stipple Bio will use its Pointillist platform to identify tumor-specific cell surface binders, which the US pharmaceutical company will combine with its oncology technologies to develop therapies across multiple modalities.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending